UAB Health, Dartmouth College, and the UAB School of Medicine are jointly launching a clinical trial of an early-stage Alzheimer’s drug to determine whether it can slow or stop the disease.
The clinical trial will test whether the drug, called moclobemide, could slow or halt the progression of Alzheimer’s disease, the university announced in a news release Monday.
The researchers will be conducting the trial at Dartmouth and in UAB’s internal medicine residency program.
The study will be funded by a grant from the National Institutes of Health, according to the news release.
Dartmouth, which opened in 2009, and UB are also partners in a similar clinical trial, the announcement said.
The UAB team will focus on the drug’s ability to slow or prevent the progression and increase survival rates of people with the disease, according the news package.
Dalton and U.S. Department of Veterans Affairs will also be participating in the study.